Thomas Hutson, DO, PharmD, FACP

Thomas Hutson, DO, PharmD, FACP, Baylor University Medical Center

Articles by Thomas Hutson, DO, PharmD, FACP
Next-Generation Therapies in RCC: Examining Tivozanib and Belzutifan
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 1, 2024
Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC.
View More
Long-Term Benefits of Tivozanib: Insights From the TIVO-3 Study
Katy Beckermann, MD, PhDRenal Cell Carcinoma | July 1, 2024
Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC.
View More
Dr. Thomas Hutson on Long-Term Durable Response After 4 Years Follow-Up in the CLEAR Study
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
View More
Dr. Thomas Hutson on Conventional and Novel Combination Therapies for First-Line Advanced RCC
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
View More

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |